Miłosz Bronowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miłosz Bronowski has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Nowak
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Anna Romac
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Jakub Janczura
Faculty of Medicine, Jan Kochanowski University, Kielce, Poland
1 shared publication - Krzysztof Łupina
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Natalia Dardzińska
Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland
1 shared publication - Paulina Jaskulska
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by IMR Press in International Journal of Pharmacology
- Vol. 22 (5)
Incretin-Based Therapies and the Associated Impact on Bone Health
Incretin-based therapies are being increasingly used in the treatment of type 2 diabetes mellitus and obesity, both of which are associated with impaired bone quality, altered skeletal remodeling, and increased fracture risk. Experimental studies suggest that incretin signaling may affect bone through osteoblast and osteoclast activity, Wnt/β-catenin signaling, adipose tissue inflammation, metabolic regulation, and the gut–bone axis. However, clinical evidence remains heterogeneous, with most studies indicating neutral or context-dependent effects on bone mineral density and fracture risk rather than consistent skeletal benefit. Interpretation is further complicated by treatment-induced weight loss, changes in lean mass and mechanical loading, diabetes-related skeletal fragility, and the limited number of trials specifically designed to assess bone endpoints. Evidence for newer dual and triple agonists is especially limited, despite their growing use and substantial weight-loss effects. Incretin-based therapies appear reassuring from a skeletal safety perspective; however, long-term studies with dedicated skeletal endpoints are needed to determine their effects on bone quality, falls, and fracture risk in high-risk populations. This review summarizes current mechanistic, preclinical, and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors on bone turnover, bone mineral density, bone quality, and fracture outcomes.
- 16 September 2026
- Published by IMR Press in International Journal of Pharmacology
- Vol. 22 (5)
Open AccessIncretin-Based Therapies and the Associated Impact on Bone Health
Incretin-based therapies are being increasingly used in the treatment of type 2 diabetes mellitus and obesity, both of which are associated with impaired bone quality, altered skeletal remodeling, and increased fracture risk. Experimental studies suggest that incretin signaling may affect bone through osteoblast and osteoclast activity, Wnt/β-catenin signaling, adipose tissue inflammation, metabolic regulation, and the gut–bone axis. However, clinical evidence remains heterogeneous, with most studies indicating neutral or context-dependent effects on bone mineral density and fracture risk rather than consistent skeletal benefit. Interpretation is further complicated by treatment-induced weight loss, changes in lean mass and mechanical loading, diabetes-related skeletal fragility, and the limited number of trials specifically designed to assess bone endpoints. Evidence for newer dual and triple agonists is especially limited, despite their growing use and substantial weight-loss effects. Incretin-based therapies appear reassuring from a skeletal safety perspective; however, long-term studies with dedicated skeletal endpoints are needed to determine their effects on bone quality, falls, and fracture risk in high-risk populations. This review summarizes current mechanistic, preclinical, and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors on bone turnover, bone mineral density, bone quality, and fracture outcomes.